NAGE (Niagen Bioscience, Inc. Common Stock) Stock Analysis - SEC Filings

Niagen Bioscience, Inc. Common Stock (NAGE) is a publicly traded Healthcare sector company. As of May 21, 2026, NAGE trades at $3.73 with a market cap of $294.68M and a P/E ratio of 17.16. NAGE moved +2.18% today. Year to date, NAGE is -41.86%; over the trailing twelve months it is -65.15%. Its 52-week range spans $3.57 to $14.69. Analyst consensus is strong buy with an average price target of $11.25. Rallies surfaces NAGE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Where can I find NAGE SEC filings?

Rallies organizes NAGE SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.

NAGE Key Metrics

Key financial metrics for NAGE
MetricValue
Price$3.73
Market Cap$294.68M
P/E Ratio17.16
EPS$0.22
Dividend Yield0.00%
52-Week High$14.69
52-Week Low$3.57
Volume7
Avg Volume0
Revenue (TTM)$129.42M
Net Income$17.38M
Gross Margin64.28%

Latest NAGE News

Recent NAGE Insider Trades

  • Pamir Ozan bought 4.46K (~$30.41K) on Nov 14, 2025.
  • Pamir Ozan bought 2.22K (~$15.21K) on Nov 14, 2025.

NAGE Analyst Consensus

4 analysts cover NAGE: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $11.25.

Common questions about NAGE

Where can I find NAGE SEC filings?
Rallies organizes NAGE SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
Does Rallies show NAGE 10-K and 10-Q filings?
Rallies organizes NAGE SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.
Is NAGE research on Rallies investment advice?
No. Rallies provides research, data, and educational context for NAGE. It does not provide personalized investment advice.
NAGE

NAGE